Header Logo

Connection

JOSEPH JANKOVIC to Torticollis

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Torticollis.
JOSEPH JANKOVIC
Connection Strength
10.152
Torticollis
  1. Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis. Toxicon. 2024 Sep; 248:108035.
    View in: PubMed
    Score: 0.865
  2. Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023 Jul 01; 102(S1):e32403.
    View in: PubMed
    Score: 0.804
  3. Secondary dystonia following parenchymal brain tumors. J Neurol Sci. 2023 03 15; 446:120577.
    View in: PubMed
    Score: 0.781
  4. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.557
  5. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93.
    View in: PubMed
    Score: 0.445
  6. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140.
    View in: PubMed
    Score: 0.358
  7. Asian over-representation among patients with hemifacial spasm compared to patients with cranial-cervical dystonia. J Neurol Sci. 2010 Nov 15; 298(1-2):61-3.
    View in: PubMed
    Score: 0.335
  8. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007 Oct; 13(7):411-6.
    View in: PubMed
    Score: 0.261
  9. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.256
  10. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006 Sep 26; 67(6):1083-5.
    View in: PubMed
    Score: 0.251
  11. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006 Apr; 9(2-3):145-8.
    View in: PubMed
    Score: 0.243
  12. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005 Sep 13; 65(5):765-7.
    View in: PubMed
    Score: 0.234
  13. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004 Mar; 19 Suppl 8:S109-15.
    View in: PubMed
    Score: 0.210
  14. Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024 02 27; 102(4):e208091.
    View in: PubMed
    Score: 0.209
  15. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003 Apr 08; 60(7):1186-8.
    View in: PubMed
    Score: 0.198
  16. Isolated Cervical Dystonia: Diagnosis and Classification. Mov Disord. 2023 08; 38(8):1367-1378.
    View in: PubMed
    Score: 0.197
  17. The Conundrum of Dystonia in Essential Tremor Patients: How does One Classify these Cases? Tremor Other Hyperkinet Mov (N Y). 2022; 12:15.
    View in: PubMed
    Score: 0.186
  18. Hold that pose: capturing cervical dystonia's head deviation severity from video. Ann Clin Transl Neurol. 2022 05; 9(5):684-694.
    View in: PubMed
    Score: 0.184
  19. Head tremor in cervical dystonia: Quantifying severity with computer vision. J Neurol Sci. 2022 Mar 15; 434:120154.
    View in: PubMed
    Score: 0.182
  20. Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother. 2001 Dec; 2(12):1985-94.
    View in: PubMed
    Score: 0.180
  21. A Multi-center Genome-wide Association Study of Cervical Dystonia. Mov Disord. 2021 12; 36(12):2795-2801.
    View in: PubMed
    Score: 0.176
  22. Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. Expert Opin Drug Saf. 2021 Jun; 20(6):695-705.
    View in: PubMed
    Score: 0.175
  23. Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia? Tremor Other Hyperkinet Mov (N Y). 2021 06 23; 11:21.
    View in: PubMed
    Score: 0.175
  24. Head tremor and pain in cervical dystonia. J Neurol. 2021 May; 268(5):1945-1950.
    View in: PubMed
    Score: 0.169
  25. It's tricky: Rating alleviating maneuvers in cervical dystonia. J Neurol Sci. 2020 Dec 15; 419:117205.
    View in: PubMed
    Score: 0.167
  26. Postural Directionality and Head Tremor in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
    View in: PubMed
    Score: 0.158
  27. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. J Neurol Sci. 2019 Oct 15; 405:116413.
    View in: PubMed
    Score: 0.153
  28. Head tremor at disease onset: an ataxic phenotype of cervical dystonia. J Neurol. 2019 Aug; 266(8):1844-1851.
    View in: PubMed
    Score: 0.150
  29. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
    View in: PubMed
    Score: 0.134
  30. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
    View in: PubMed
    Score: 0.126
  31. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 05 10; 86(19):1818-26.
    View in: PubMed
    Score: 0.122
  32. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.121
  33. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
    View in: PubMed
    Score: 0.119
  34. IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
    View in: PubMed
    Score: 0.108
  35. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014 Aug; 85(8):882-4.
    View in: PubMed
    Score: 0.107
  36. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
    View in: PubMed
    Score: 0.106
  37. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.090
  38. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
    View in: PubMed
    Score: 0.088
  39. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN?, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9.
    View in: PubMed
    Score: 0.088
  40. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011 Jul; 216(7):782-92.
    View in: PubMed
    Score: 0.084
  41. Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans. Autoimmunity. 2011 May; 44(3):167-76.
    View in: PubMed
    Score: 0.083
  42. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23.
    View in: PubMed
    Score: 0.080
  43. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
    View in: PubMed
    Score: 0.071
  44. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
    View in: PubMed
    Score: 0.071
  45. Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008 May; 26 Suppl 1:43-53.
    View in: PubMed
    Score: 0.070
  46. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb; 44(5):1029-41.
    View in: PubMed
    Score: 0.061
  47. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
    View in: PubMed
    Score: 0.058
  48. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005 Mar; 20(1):44-7.
    View in: PubMed
    Score: 0.056
  49. Cervical dystonia as the initial presentation of Huntington's disease. Mov Disord. 1996 Jul; 11(4):457-9.
    View in: PubMed
    Score: 0.031
  50. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007 Jan-Feb; 20(1):15-21.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.